Critical insights into how melanoma tumors resist BRAF inhibitors were gained from two back-to-back studies. Two key areas are the cell-signaling pathways BRAF-mutant melanoma cells use to become resistant to inhibitor drugs and to evolve and develop drug resistance.
A T-cell activation molecule can be used as a biomarker to identify rare antitumor T cells in human cancers, according to new research.
A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers.
The risk of melanoma was significantly increased with personal history of PCa, whereas the risk of non-melanoma skin cancer was marginally increased with PCa.
Phenotype switching may be involved in changing the appearance of melanoma tumors by altering the number and type of protein receptors that dot the surface of the individual melanoma cells within a tumor.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|